Daniel Almeida, a PhD student under the supervision of Dr. Gustavo Turecki in McGill University’s Integrated Program in Neuroscience and at the Douglas Research Centre, was included in Forbes Magazine’s Top 30 under 30 list, unveiled December 3. Overall, the ninth annual list includes 600 young entrepreneurs, risk-takers and game changers who are redefining what it means to innovate and lead by example.
Category:
Published on: 6 Dec 2019
Montreal — In a study published in Stem Cell Reports, a McGill team of scientists led by Dr. Carl Ernst, researcher at the Douglas Hospital Research Centre, revealed a molecular mechanism that may play a role in the development of autism.
Category:
Published on: 26 Jun 2018
KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC
KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.
Category:
Published on: 3 Oct 2016
